Dr. Elba Etchebehere, nuclear doctor, lead researcher at CEPID Cancerthera and professor at the Faculty of Medical Sciences at UNICAMP (FCM/UNICAMP), was appointed to compose the working group on “Integration of Primary Health Care and Universal Coverage of Health” Global Diagnostics Coalition (GDC). The appointment, carried out under the indication of the World Federation of Nuclear Medicine and Biology, recognizes the trajectory of the researcher in the implementation of resolutions of the World Health Assembly (AMS).
The occupation of posts in international instances transcends the individual recognition of the researcher. “This movement reinforces the role of Brazilian science in the global scenario, ensuring that the realities and needs of developing countries are considered in the formulation of clinical guidelines and public policies”, evaluates Etchebehere.
The performance of researchers who move between the bench and institutional governance, as is the case of Etchebehere, thus becomes a strategic differential, since it is in this dialogue that technical knowledge becomes political influence, allowing scientific innovation to advance in a democratic way and is effectively incorporated. to health systems.
The teacher’s presence at the GDC reinforces CancerThera’s commitment to translational innovation and the articulation of policies that guarantee safe and evidence-based access to diagnostic and therapeutic technologies, consolidating the role of brazilian research in the construction of global health agendas.
Strategic action and impact on the health system
GDC, a network managed by the World Health Organization (WHO), acts as a collaborative platform that brings together international organizations, academic institutions and civil society to overcome barriers to access to global diagnoses. The working group Etchebehere joins has as its central mission to translate global standards into national policies, promoting consistent integration of diagnostics into benefit packages and health care strategies.
In this context, the researcher’s specific contribution will be to bring the perspective of nuclear medicine to the debate on international public policies, guiding how advanced diagnostic technologies can — and should — be integrated into health systems to optimize early diagnosis and oncological care.
As a member of the group, Etchebehere will contribute to the development of practical tools, case studies and support mechanisms so that countries can incorporate essential diagnoses into their healthcare systems, reducing the gap between the global technology availability and real access at the tip. The work aims to ensure that diagnoses are seen not only as isolated parts, but as an essential pillar for equity and strengthening of the Unified Health System (SUS) and other health systems.
“Participating in this initiative is a unique opportunity to position nuclear medicine where global decisions take place, helping to translate scientific evidence into sustainable and accessible health practices”, highlights the researcher.
Text: Xenya Bucchioni
